[Payment of Filing Fee (Check the appropriate box): x No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies:]
[Payment of Filing Fee (Check the appropriate box): x No fee required. o Feemputed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies: 2)gregate number of securities to which transaction applies: 3) 4) Proposed maximumgregate value of transaction:]
[Payment of Filing Fee (Check the appropriate box): x No fee required. o Feemputed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies: 2)gregate number of securities to which transaction applies: 3) 4) Proposed maximumgregate value of transaction:]
[R E C I T A L S NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows: 1. Amendment (a) deleting Sections 3(e) and (f) and replacing it with the following: Issuance of Additional Shares of Common Stock subsections (a) through (d) of this Section 3] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 30, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Section 8 –]
[November 23, 2010 Division of Corporate Finance 100 F. Street, N.E. Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated October 29, 2010, regarding the above-referenced]
[November 23, 2010 Division of Corporate Finance 100 F. Street, N.E. Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated October 29, 2010, regarding the above-referenced]
[NEWS RELEASE Skystar Bio-Pharmaceutical Announces Record Organic Revenues of $18.5 Million For Third Quarter Fiscal Year 2010 - Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million - XI’AN, CHINA – November 16, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2010 Highlights · Revenue increases 45% YoY to record $18.5 million ·]
[NEWS RELEASE Skystar Bio-Pharmaceutical Announces Record Organic Revenues of $18.5 Million For Third Quarter Fiscal Year 2010 - Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million - XI’AN, CHINA – November 16, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2010 Highlights · Revenue increases 45% YoY to record $18.5 million ·]
[Sinovac Reports Unaudited Third Quarter 2010 Financial Results - Conference call scheduled for Monday, November 15, 2010 at 8:00 AM EST Beijing November 15, 2010 Sinovac Biotech Ltd. ( NASDAQ: SVA), a leading provider of biopharmaceutical products in China , announc ed today its un audited financial results for the three-month and nine-month periods ended September 30,] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
[Sinovac Reports Unaudited Third Quarter 2010 Financial Results - Conference call scheduled for Monday, November 15, 2010 at 8:00 AM EST Beijing November 15, 2010 Sinovac Biotech Ltd. ( NASDAQ: SVA), a leading provider of biopharmaceutical products in China , announc ed today its un audited financial results for the three-month and nine-month periods ended September 30,] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
